Literature DB >> 33856880

The Societal Value of Vaccination in the Age of COVID-19.

David E Bloom1, Daniel Cadarette1, Maddalena Ferranna1.   

Abstract

In recent years, academics and policymakers have increasingly recognized that the full societal value of vaccination encompasses broad health, economic, and social benefits beyond avoided morbidity and mortality due to infection by the targeted pathogen and limited health care costs. Nevertheless, standard economic evaluations of vaccines continue to focus on a relatively narrow set of health-centric benefits, with consequences for vaccination policies and public investments.The COVID-19 pandemic illustrates in stark terms the multiplicity and magnitude of harms that infectious diseases may inflict on society. COVID-19 has overtaxed health systems, disrupted routine immunization programs, forced school and workplace closures, impeded the operation of international supply chains, suppressed aggregate demand, and exacerbated existing social inequities.The obvious nature of the pandemic's broad effects could conceivably convince more policymakers to identify and account for the full societal impacts of infectious disease when evaluating the potential benefits of vaccination. Such a shift could make a big difference in how we allocate societal resources in the service of population health and in how much we stand to gain from that spending.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33856880      PMCID: PMC8101582          DOI: 10.2105/AJPH.2020.306114

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  7 in total

1.  A Social Media‒Based Public Health Campaign Encouraging COVID-19 Vaccination Across the United States.

Authors:  Isabella de Vere Hunt; Tamara Dunn; Megan Mahoney; Michael Chen; Vanessa Nava; Eleni Linos
Journal:  Am J Public Health       Date:  2022-07-07       Impact factor: 11.561

2.  Key predictors of COVID-19 vaccine hesitancy in Malaysia: An integrated framework.

Authors:  Jason Wei Jian Ng; Santha Vaithilingam; Mahendhiran Nair; Li-Ann Hwang; Kamarul Imran Musa
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

3.  Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status.

Authors:  Piotr Seiffert; Adam Konka; Janusz Kasperczyk; Jacek Kawa; Mateusz Lejawa; Barbara Maślanka-Seiffert; Joanna Zembala-John; Monika Bugdol; Małgorzata Romanik; Rafał Bułdak; Czesław Marcisz; Jarosław Derejczyk; Dorota Religa
Journal:  Biogerontology       Date:  2021-12-19       Impact factor: 4.277

4.  The prioritation and gap of preoperative COVID-19 vaccination in cancer surgery of the breast, head and neck, and skin: A cohort study of 367 patients in an Indonesian hospital.

Authors:  Sumadi Lukman Anwar; Roby Cahyono; Herjuna Hardiyanto; Suwardjo Suwardjo; Darwito Darwito; Wirsma Arif Harahap
Journal:  Ann Med Surg (Lond)       Date:  2021-11-18

5.  Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.

Authors:  Anat Achiron; Mathilda Mandel; Michael Gurevich; Sapir Dreyer-Alster; David Magalashvili; Polina Sonis; Mark Dolev; Shay Menascu; Gil Harari; Shlomo Flechter; Rina Falb
Journal:  J Neurol       Date:  2022-03-02       Impact factor: 6.682

Review 6.  Seasonal influenza in children: Costs for the health system and society in Europe.

Authors:  Leonardo Villani; Floriana D'Ambrosio; Roberto Ricciardi; Chiara de Waure; Giovanna Elisa Calabrò
Journal:  Influenza Other Respir Viruses       Date:  2022-04-15       Impact factor: 5.606

7.  A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.

Authors:  Hannah C Moore; Jeffrey W Cannon; David C Kaslow; Theresa Lamagni; Asha C Bowen; Kate M Miller; Thomas Cherian; Jonathan Carapetis; Chris Van Beneden
Journal:  Clin Infect Dis       Date:  2022-09-30       Impact factor: 20.999

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.